These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38470964)

  • 1. Progressive hyperpigmentation and lentigines due to KIT variants improving with imatinib.
    Liang L; Peng S; Huang S; Wang H; Lin Z
    Br J Dermatol; 2024 Jun; 191(1):148-149. PubMed ID: 38470964
    [No Abstract]   [Full Text] [Related]  

  • 2. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
    Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
    Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
    Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
    Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
    [No Abstract]   [Full Text] [Related]  

  • 4. Familial gastrointestinal stromal tumors, lentigines, and café-au-lait macules associated with germline c-kit mutation treated with imatinib.
    Gupta D; Chandrashekar L; Larizza L; Colombo EA; Fontana L; Gervasini C; Thappa DM; Rajappa M; Rajendiran KS; Sreenath GS; Kate V
    Int J Dermatol; 2017 Feb; 56(2):195-201. PubMed ID: 28074523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autosomal dominant progressive hyperpigmentation and lentigines in a Japanese pedigree due to a missense mutation near the C-terminus of KIT.
    Takeichi T; Sugiura K; Tanahashi K; Noda K; Kono M; Akiyama M
    Br J Dermatol; 2018 Nov; 179(5):1210-1211. PubMed ID: 29923175
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple lentigines and cutaneous hyperpigmentation caused by a KIT mutation.
    Jiang X; Lin Z; Wang H
    Br J Dermatol; 2020 Nov; 183(5):e148. PubMed ID: 32716058
    [No Abstract]   [Full Text] [Related]  

  • 7. Generalized lentigines associated with familial gastrointestinal stromal tumors dramatically improved by imatinib treatment.
    Hasegawa M; Shimizu A; Ieta K; Shibusawa K; Ishikawa O; Ishida-Yamamoto A; Tamura A
    J Dermatol; 2020 Jun; 47(6):e241-e242. PubMed ID: 32220019
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous hyperpigmentation and familial gastrointestinal stromal tumour associated with KIT mutation.
    Wali GN; Halliday D; Dua J; Ieremia E; McPherson T; Matin RN
    Clin Exp Dermatol; 2019 Jun; 44(4):418-421. PubMed ID: 30280421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
    McKean M; Oba J; Ma J; Roth KG; Wang WL; Macedo MP; Carapeto FCL; Haydu LE; Siroy AE; Vo P; Hong DS; Eterovic AK; Patel KP; Bassett RL; Grimm EA; Lazar AJ; Woodman SE
    J Invest Dermatol; 2019 Mar; 139(3):728-731. PubMed ID: 30798855
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imatinib-induced pigmentation of the hard palate].
    Kluger N; Cassier P; Ruffion N
    Ann Dermatol Venereol; 2018 Nov; 145(11):723-724. PubMed ID: 30472997
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
    Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
    Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
    J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
    [No Abstract]   [Full Text] [Related]  

  • 19. A new KIT gene mutation in thymic cancer and a promising response to imatinib.
    Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
    Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
    Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.